Hilser T, Gruenwald V, Bergmann L, Goebell P, Strauss A, Meiler J, Hartmann A, Ivanyi P, Bedke J (2022)
Publication Type: Conference contribution
Publication year: 2022
Publisher: KARGER
City/Town: BASEL
Pages Range: 101-101
Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT
APA:
Hilser, T., Gruenwald, V., Bergmann, L., Goebell, P., Strauss, A., Meiler, J.,... Bedke, J. (2022). A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (Everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study of the IAG-N). In ONCOLOGY RESEARCH AND TREATMENT (pp. 101-101). BASEL: KARGER.
MLA:
Hilser, Thomas, et al. "A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (Everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study of the IAG-N)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2022. 101-101.
BibTeX: Download